TiumBio to present positive merigolix phase 2 results at ESHRE 2025

TiumBio announced Wednesday that it will present clinical trial results for merigolix (TU2670), a drug in development for the treatment of endometriosis and uterine fibroids, at the upcoming European Society of Human Reproduction and Embryology (ESHRE) Congress.

The ESHRE Annual Meeting will take place from June 29 to July 2 in Paris, France. Alongside the American Society for Reproductive Medicine (ASRM), ESHRE is recognized as a leading international society in the field of reproductive medicine.

TiumBio said it will present findings from the European phase 2a study of merigolix (TU2670) in endometriosis during a session titled “Breaking boundaries in endometriosis: from the microbiome to maternal outcomes,” which will highlight new approaches and therapies in endometriosis research. The presentation will be led by the study’s principal investigator, Dr. Krzysztof Szymanowski of Poland.

Merigolix, a drug candidate for endometriosis and uterine fibroids that met its primary endpoint in phase 2 clinical trials for both indications, showed a dose-dependent treatment effect in the high-dose group. This outcome, combined with the drug’s plausible mechanism of action, reinforces its therapeutic potential, according to the company.

Additionally, merigolix showed positive results in key secondary endpoints: improvement in non-menstrual pelvic pain (NMPP) in the endometriosis trial, and increases in hemoglobin levels along with reductions in uterine fibroid size in the fibroid trial. The drug also demonstrated overall safety and tolerability.

“We are very pleased to have the opportunity to share merigolix’s clinical performance and therapeutic potential directly with world-renowned experts at this meeting,” said Kim Hun-taek, CEO of TiumBio. “The positive clinical results in both endometriosis and uterine fibroids further enhance the value of merigolix as a new drug.”